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Endostatin, a carboxy-terminal fragment of collagen XVIII, potently inhibits angiogenesis and tumour growth, presumably through
induction of apoptosis in endothelial cells and/or inhibition of their migration. Here we have tested how the timing of recombinant
human endostatin (rh-E) administration affects its antitumour activity in a liver metastasis model of mouse C26 colorectal carcinoma
cells. The effects of rh-E treatment on hepatic tumour load and on early tumour cell seeding were evaluated. Recombinant human
endostatin was most effective in reducing intrahepatic tumour growth when administered prior to tumour cell inoculation. Analysis of
early tumour cell seeding by using [
125I]iododeoxyuridine-labelled C26 cells or by in vivo microscopy showed that rh-E reduced
tumour cell seeding in the liver sinusoids. Recombinant human endostatin did not inhibit tumour growth when administered later
than 4 days after tumour injection. Pretreatment of human umbilical vein endothelial cells with rh-E in vitro reduced C26 tumour cell
adhesion under flow conditions two-fold as assessed by video microscopy and multiphoton laser scanning microscopy. Our results
show that rh-E, in addition to antiangiogenic effects, reduces tumour cell adhesion in the liver sinusoids during the very early phases of
metastasis formation. These data point towards a previously unknown mode of action of endostatin, that is, its ability to interfere with
tumour cell seeding. Such insights may be helpful in the design of trials to improve (surgical) treatment of colorectal carcinoma and
liver metastases.
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Antiangiogenic drugs are directed against components of the
developing vasculature. Based on the working mechanism of these
drugs, that is, preventing outgrowth of microscopic tumour
deposits, little or no antitumour effects might be anticipated in
gross or bulky (metastatic) disease. In the case of established
(unresectable) tumours, treatment with antiangiogenic agents will
at best lead to disease stabilisation, rather than to complete tumour
remission. Furthermore, discontinuation of therapy will allow the
tumour or its metastases to resume their outgrowth (Boehm et al,
1997). Taken together, initiation of the treatment already during
the initial phase of tumour growth can be essential in optimising
antiangiogenic therapy.
Endostatin, a naturally occurring fragment of collagen XVIII, is
one of the most effective inhibitors of angiogenesis and
dramatically reduced tumour growth in several mouse models
with no serious side effects observed (Boehm et al, 1997; O’Reilly
et al, 1997; Kisker et al, 2001). However, endostatin was ineffective
in other studies, and these data have prompted the discussion
about the efficacy of endostatin (Marshall, 2002). In a previous
report by our group, endostatin treatment resulted in significant
antitumour effects in a model of murine colorectal liver metastases
(te Velde et al, 2002). These effects, as measured 12 days following
tumour cell injection by histology, were achieved by administra-
tion of endostatin from day 0 until day 12. Others found that the
efficacy of endostatin improved when administered before tumour
cell injection, as measured by tumour load 21 days following
tumour cell injection (Solaun et al, 2002). In a pilot study, we have
observed that endostatin efficacy depended on the timing of its
administration. We were not able to show regression of already
established colorectal liver metastases when endostatin treatment
was initiated 7 days after tumour cell injection.
To optimise the timing of endostatin administration, it is
imperative that its mechanism of action is resolved. So far,
endostatin is known to have antiangiogenic properties, that is, its
antitumour effects depend on inhibition of developing tumour
vasculature. This action has predominantly been ascribed to
inhibition of apoptosis and migration of endothelial cells
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s(Yamaguchi et al, 1999; Sasaki et al, 2002). Many studies point
towards an effect of endostatin on the adhesion of endothelial cells
to other endothelial cells (Dixelius et al, 2002): these inhibitory
effects may be mediated by direct blocking of specific integrins
(Rehn et al, 2001; Furumatsu et al, 2002), by disassembly of focal
adhesions and actin stress fibres (Wickstrom et al, 2001) and/or by
antagonising the Wnt pathway (Hanai et al, 2002). Based on these
studies, we hypothesised that (antiadhesive) antitumour properties
of endostatin could play a role even shortly after tumour cell
inoculation, before new vessel formation is needed for tumour
outgrowth. Very recently, others showed that endostatin affects
melanoma cells while metastasising to the liver in an experimental
setting (Mendoza et al, 2004).
In this study, we have investigated the influence of endostatin on
the early spatiotemporal fate of murine colon carcinoma cells
metastasising to the liver. We show that administration of
recombinant human endostatin (rh-E) prior to tumour cell
injection resulted in reduced tumour cell seeding in the liver and
in reduced intrahepatic tumour growth. Furthermore, rh-E
induced a two-fold decrease of tumour cell adhesion to endothelial
cells under flow conditions in vitro.
MATERIALS AND METHODS
Endostatin
Recombinant human endostatin was produced in Pichia pastoris
(Courtesy of Entremed, Rockville, USA). In mice, 500mg was
administered by daily subcutaneous (s.c.) injection of 100ml.
Control animals received the equal amount of solvent citrate buffer
(17mM citric acid, 59mM NaCl, 66mM Na2PO4, pH 6.2).For the in
vitro experiments, three equivalent dosages of endostatin and its
control were used, that is, 400, 200 and 100mgml
 1. Only freshly
thawed endostatin was used in the experiments presented.
Tumour cell culture
The murine colon carcinoma cell line C26 was routinely cultured
in Dulbecco’s modified Eagle’s medium (DMEM) supplemented
with 10% heat-inactivated fetal calf serum (FCS), 100Uml
 1
penicillin and 100mgml
 1 streptomycin in a 10% CO2 environ-
ment. Cell viability was determined by Trypan blue staining.
Confluent cultures were harvested by brief trypsinisation (0.05
trypsin in 0.02% EDTA), and resuspended in phosphate-buffered
saline (PBS) to a final concentration of 10
6 1.0cellsml
 1 (unless
stated otherwise).
Endothelial cell culture
Human vascular endothelial cells (HUVECs) were isolated from
human umbilical veins. Cells were cultured in endothelial basal
medium (EBM) containing EGM-2 medium (Clonetics, Bio Whi-
taker, San Diego, CA, USA) supplemented with 5% FBS,
gentamicin, amphotericin B, hydrocortisone, ascorbic acid and
the following growth factors: VEGF, bFGF, hEGF and IGF-1. Cells
of passage two were seeded on fibronectin-coated glass coverslips
and grown until confluency.
In vivo liver metastases model
Balb/C male mice (aged 10 weeks) purchased from Harlan
(Leicestershire, Great Britain) were housed under standard
conditions and allowed food and water ad libitum. Colorectal
liver metastases were induced in all mice as follows (te Velde et al,
2002). Mice were anaesthetised intraperitoneally with fentanyl
citrate/fluanisone (0.3mg per mouse; Janssen-Cilag, Brussels,
Belgium) and midazolamchloride (12.5mg per mouse; Roche,
Brussels, Belgium). Through a left lateral flank incision, C26
colorectal carcinoma cells were injected into the spleen paren-
chyma. In case mice were allowed to survive 24h, the spleen was
removed after 10min to avoid intrasplenic tumour growth. All
experiments were performed in accordance with the guidelines of
the Animal Welfare Committee of the UMC Utrecht, The Nether-
lands, as well as with those of the UKCCCR guidelines on the
treatment of animals, and all animals received humane care.
Histological analysis
To determine the effects on tumour load of different schemes of
endostatin administration, mice (n¼24) were randomly assigned
to the following experimental groups: endostatin treatment
starting 2h before tumour cell injection and 8h, 4 days and 7
days after tumour cell injection. The treatment was discontinued
on days 4 and 12. Lower concentrations of tumour cells were used
for treatment groups until day 19 (10
5 1.0ml
 1). For histological
analysis of tumour burden, the mice were killed on days 7, 12 or 19
(n¼3 per group). The livers were harvested, formaldehyde
fixed and embedded in paraffin. Intrahepatic tumour load was
scored as the hepatic replacement area (HRA), the percentage of
hepatic tissue having been taken up by metastatic tumour cells.
This was assessed on nonsequential haematoxylin- and eosin-
stained sections by semiautomated stereology (Leica-Q-Prodit
system, Leica Microsystems, Rijswijk, The Netherlands) using a
four points grid overlaid on 100 fields per slide at a magnification
of  40.
Intrahepatic detection of radiolabelled tumour cells
To determine the spatiotemporal fate of tumour cells metastasising
to the liver, we used radiolabelled tumour cells. To prepare labelled
cells for intrasplenic injection, C26 tumour cells were cocultured
with 1mCiml
 1 [
125I]iododeoxyuridine (Amersham Biosciences,
Weert, The Netherlands) in DMEM containing 5% FCS for 72h at
371C in 10% CO2 environment. The cells were washed in PBS,
detached with trypsin-EDTA, washed with serum-containing
media and twice with PBS and resuspended to a final concentra-
tion of 10
6 5.3cellsml
 1 in PBS.
Intrasplenic injection of [
125I]iododeoxyuridine-labelled tumour
cells was followed by hepatectomy at t¼15min and 1h (n¼5 per
group per time point per experiment). The resected livers were
rinsed in 70% ethanol. Radioisotope levels were measured by a
gamma counter and expressed as percentage of the input dose
(Cpma). The input dose was determined by measuring two 100-ml
aliquots of PBS containing [
125I]iododeoxyuridine-labelled tumour
cells in parallel with the liver samples (100%).
In vivo microscopy
To examine the fate of tumour cells in the liver after intrasplenic
injection by in vivo microscopy, C26 cells were labelled with a
fluorescent probe, carboxyfluorescein succinyl ester (CFSE;
Molecular Probes, Leiden, The Netherlands). Tumour cells were
incubated for 15min at 371C with 20ml of 4% CFSE in PBS
containing 0.1% bovine serum albumin (BSA). Cells were
centrifuged, resuspended in DMEM and incubated for 30min at
371C. Cells were then centrifuged and resuspended for intrasplenic
injection. A fraction of tumour cells was cultured in parallel to
confirm fluorescence in 99% of the cells.
At 15min and 1h after intrasplenic injection of C26 tumour
cells, intravital fluorescence microscopy was performed using a
Nikon TE-300 inverted microscope (Uvikon, The Netherlands)
equipped with a filter set for fluorescein (excitation 450–490nm,
emission 4515nm). Images were registered with a charge coupled
device camera (Exwave HAD, Sony, The Netherlands) and
recorded with an s-VHS VCR (Panasonic). Using a high
magnification  40 lens, 10–15 randomly selected fields were
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schosen in each animal (n¼20 mice); images were recorded for
1min and were analysed off-line. At indicated time points, the
extent of metastasis was measured as number of tumour cells per
high-power field (hpf).
Tumour cell migration assay
The C26 tumour cells were grown to 75–90% confluency. After
washing, the cells were trypsinised, pelleted and resuspended in
DMEM/0.1% BSA. The cells were labelled in situ with 10mM
Calcein-AM in DMEM for 15min at 371C and subsequently added
to 8mm FALCON
s HTS FluoroBlokt Cell Culture Insert (Becton,
Dickinson and Company, Franklin Lakes, NJ, USA), at a density of
100000cells per insert. We used DMEM supplemented with 10%
FCS as a chemoattractant in the lower wells, while DMEM/0.1%
BSA was added to the control wells. Different concentrations of
endostatin (100 and 400mgml
 1) or equal concentrations of
control buffer were added. The inserts were incubated for 15min,
1h, 4h and 24h at 371C. The number of migrated cells was
measured using a PE Biosystems CytoFluor 4000 plate reader at a
gain setting of 54.
Tumour cell death assay
Tumour cells were exposed to different concentrations of
endostatin (400, 200 and 100mgml
 1) in culture medium for
24h. The total pool of adherent and detached cells was obtained by
collecting the detached cells. The remaining adherent cells were
trypsinised and added to the detached cells in the medium. One
half of the cells were stained with 0.02% Trypan blue and the
percentage of dead (Trypan blue-positive) cells was assessed using
aB u ˆrker glass counter chamber. Duplicate samples were analysed.
In addition, the other half of the cells was fixed in the culture
medium using 3.7% formaldehyde and analysed.
Tumour cell adhesion assay under flow conditions
The effects of endostatin on the in vitro adhesion of C26 tumour
cells to stimulated HUVECs were assessed under flow conditions.
The HUVECs were stimulated with TNF-a (PeproTech, London,
England) at a concentration of 10ngml
 1 for 3h before tumour
cell perfusion. At 2h before perfusion, the stimulated HUVECs
were incubated with endostatin at a concentration of 400mgml
 1,
an equal concentration of BSA or citrate buffer only.
First, the adhesion of C26 colon carcinoma cells
(10
6 4.0cellsml
 1, 1% FCS, 25mM Hepes buffer) to endostatin
(n¼7) vs citrate buffer (n¼8)-treated TNF-a-stimulated HUVECs
was investigated using a modified form of a transparent perfusion
chamber (Brandsma et al, 2002). Data from two independent
experiments were pooled. The microchamber has a slit height of
0.2mm and a width of 2mm and contains a plug on which a
coverslip (18mm 18mm) with confluent HUVECs was mounted.
C26 colon carcinoma cells were aspirated from a reservoir through
the perfusion chamber with a Harvard syringe pump (Harvard
Apparatus, South Natic, MA, USA). In this way, the flow rate
through the chamber could be controlled precisely. The wall shear
stress (t) was 50mPa. During the perfusion, the flow chamber was
mounted on a microscope stage (DM RXE, Leica, Wetzlar,
Germany), equipped with a B/W CCD video camera (Sanyo,
Osaka, Japan) connected to a VHS video recorder. Perfusion
experiments were recorded real time on a videotape. Video images
were analysed off-line for the number of adherent C26 colon
carcinoma cells with a Quantimet 570C image analysis system
(Leica Cambridge, Cambridge, UK). The number of surface-
adherent C26 cells per mm
2 was measured after 5min of perfusion
at a minimum of 25 fields (total surface X1.0mm
2) using custom-
made software developed in Optimas 6.1 (Media Cybernetics
Systems, Silver Spring, MD, USA).
Second, adhesion of C26 colon carcinoma cells to HUVECs was
determined in whole blood (Sixma et al, 1998). The HUVECs were
seeded on glass coverslips of size 60 24mm and grown to
confluency. They were perfused in a small parallel-plate perfusion
chamber with a slit height of 0.1mm and a slit width of 2mm
corresponding with flow rates of 15mlmin
 1 (shear rate 10s).
Fresh blood from healthy donors was anticoagulated with 1/10
volume of 150Uml
 1 Orgaran (a low-molecular-weight heparinoid
(LMWH); Organon, Oss, The Netherlands). Blood was prewarmed
at 371C for 10min and was then drawn through the perfusion
chamber by a Harvard infusion pump (pump 22, model 2400-004;
Natick, MA, USA). Tumour cells (10
6 6.0ml
 1) were incubated
with 200mgml
 1 dihydroethidium (3,8-diamino-5,6-dihydro-5-
ethyl-6-phenylphenanthridine 2,7-diamino-10-ethyl-9-phenyl-9,10-
dihydrophenanthridine hydroethidine). Aliquots of 15ml tumour
cells in 150ml blood were used per perfusion. Real-time images
were recorded using a VCR system and were analysed off-line and
the number of adhered tumour cells per mm
2 confluent HUVEC
layer was calculated. After perfusion, full blood perfused coverslips
were fixed in a mixture of 2% paraformaldehyde and
0.2% glutaraldehyde in 0.1moll
 1 phosphate buffer (pH 7.4).
Staining of cytoskeletal actin was performed by Phalloidin-TRITC.
Hoechst 33342 was used for blue nuclear staining, and anti-
fibrinogen was stained green (primary antibody rabbit anti-human
anti-fibrinogen). The coverslips were mounted by fluorescence
medium, FluorSavet (Calbiochem 345789, La Jolla, CA, USA). The
stained coverslips were analysed using multiphoton laser scanning
microscopy.
Statistical analysis
For comparison of the endostatin treatment and the controls, the
independent sample t-test was used. Data were given as mean7s.e.m.
and were considered significant when Po0.05.
RESULTS
Histological analysis of liver metastases
Intrahepatic arrest and outgrowth of circulating tumour cells is a
multistep process. Mice were injected with C26 tumour cells in the
spleen to induce liver metastases and treated with endostatin at
different time points. After 12 days, livers were removed and
analysed for the extent of replacement of liver tissue by tumour
cells (HRA). On day 12, the HRA of the controls (buffer treated)
was 6072.9 (Figure 1A). The HRA in mice that were treated with
endostatin from 2h prior to tumour cell injection until killing was
the lowest: 1972.1% (Po0.001). When treatment was started 2h
before tumour cell injection and replaced by citrate buffer from
day 4 until day 12, the HRA was still significantly decreased
(1573.5%, P¼0.001). When treatment was started 8h after
tumour cell injection and continued until day 12, there was a
significant antitumour effect as well (HRA 3273.4%, P¼0.002).
However, initiation of the treatment on day 4 or later after tumour
cell injection did not result in antitumour efficacy as reflected by
HRA (36.7710.1%, P¼0.139). Treatment from day 7 until day 19
did not reduce tumour load and resulted in an HRA of 38.377.3 vs
41710% in the citrate buffer-treated controls (P¼0.8) (Figure 1A
and B).
Intrahepatic detection of radiolabelled tumour cells
The above results suggest that endostatin acts at a very early stage
of metastasis formation. To investigate the initial arrest of
circulating C26 tumour cells in the liver of endostatin-pretreated
mice, we measured radiolabelled tumour cells after injection into
the spleen. Livers were collected at 15 and 60min after tumour cell
injection and the radioactivity was subsequently determined. Data
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sfrom two independent experiments were pooled. In all, 50% of the
intrasplenic injected tumour cells were arrested in the liver during
the first 15min, as measured by radioactivity. Endostatin
pretreatment reduced the percentage of injected dose in the liver
to 34.475.6% at 15min after tumour cell injection vs 57.472.5%
in the controls (P¼0.001; Figure 2). When radiolabelled cells in
the liver were measured after 1h, these percentages had not
significantly changed (37.675.2 vs 54.873.2%).
In vivo microscopy
Initial tumour cell arrest in the liver was studied in more detail by
in vivo microscopy. C26 tumour cells were fluorescently labelled
with calcein and injected into the spleens of recipient mice.
Tumour cells reaching the liver were easily discernable from the
hepatic tissue (Figure 2). Two independent experiments were
pooled (n¼20). At 15min after injection of tumour cells into the
spleen, the control mice showed a mean of 7.370.6 fluorescent
tumour cells per hpf (Figure 3A), whereas in the mice that were
treated with endostatin 2h prior to injection, less arrested
intrahepatic cells (3.270.5cellshpf
 1) were counted (Po0.001;
Figure 3B). When images were made 1h after tumour cell
injection, this reduction was unchanged (endostatin-treated livers
2.770.3 arrested cells per hpf vs controls 7.470.7 cells per hpf,
Po0.001). No differences were observed within either treatment
group between the two time points 15min and 1h after tumour cell
injection (controls 15min vs 1hP¼0.93; endostatin 15min vs 1h
P¼0.39).
Tumour cell assay
Significant Calcein-AM labelled C26 chemotaxis was not detected
until 2h of incubation. The migration of endostatin-treated as
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Figure 1 (A) Endostatin (rh-E) therapy is most efficacious when started
prior to tumour cell seeding. All mice were inoculated with tumour cells on
t0. Recombinant human endostatin or control citrate buffer was given in
different time schemes as indicated and the intrahepatic tumour load
(HRA) for all different treatment groups was assessed on day 12. Data are
plotted as means7s.e.m. (B) Reduced therapeutic efficacy of rh-E
treatment on established tumours. (a) Haematoxylin- and eosin-stained
sections from a liver 7 days after intrasplenic injection of tumour cells just
prior to the start of treatment, showing three small intrahepatic tumour
lesions (dark nodules). (b) Tumour-bearing liver 19 days after tumour cell
injection treated with citrate buffer. (c) Tumour-bearing liver 19 days after
tumour cell injection treated with rh-E. The tumours continued to grow
under rh-E treatment. For quantification, see (A).
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Figure 2 Radioactive labelled tumour cells in the liver, 15min and 1h
after intrasplenic injection, as measured by gamma counter and
represented as percentage of injected [
125I]iododeoxyuridine-labelled
tumour cells. At 15min after tumour cell injection in the spleen, the
percentage of injected dose in the liver was 34.475.6% in the mice that
were treated with rh-E 2h prior to tumour cell injection, vs 57.472.5% in
the controls (P¼0.001). After 1h, these percentages had not significantly
changed.
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scompared to the control tumour cells was similar at all time
points measured. At the time of maximal migration – at 4h – the
lowest concentration of endostatin resulted in a fluorescent signal
of the migrated cells of 61657926 vs 56207765 in the controls
(P¼0.6). The highest concentration of endostatin did not
influence the migration of tumour cells either (556271018 vs
52687623 in the controls, P¼0.8). There was no direct effect of
endostatin on cell death of C26 murine colon carcinoma cells (data
not shown).
Tumour cell adhesion assay under flow conditions
Since endostatin treatment decreased early intrahepatic
tumour cell arrest and did not directly influence tumour cell
death or migration, we investigated tumour cell–endothelial
cell interactions. Fluorescent-labelled tumour cells were perfused
over a confluent layer of endothelial cells. Pretreatment (2h)
with endostatin of stimulated HUVECs led to a more than
two-fold decrease of tumour cell adhesion under flow
conditions (103718adhered cellsmm
 2) as compared to
pretreatment with control buffer (180715adhered cellsmm
 2,
P¼0.007). Shear forces did not induce rolling of the C26 cells,
but rather a direct tethering, followed by firm tumour cell
adhesion under both control and endostatin conditions. Bovine
serum albumin did not inhibit adhesion of tumour cells to
HUVECs (data not shown). In concordance, after perfusion
with full blood, the adhesion of C26 cells to HUVECs was
inhibited with endostatin pretreatment (143720adhered cells
mm
 2) vs controls (239741adhered cellsmm
 2)( P¼0.0231).
Multiphoton laser scanning microscopy visualised the adhesion of
tumour cells, surrounded by platelets, to endothelial cells
(Figure 4). Reduced tumour cell adhesion by endostatin pretreat-
ment was not associated with detectable changes in tumour or
endothelial cell morphology or viability, nor with reduced platelet
adhesion.
DISCUSSION
Several mechanisms have been proposed that might explain
the antiangiogenic activity of endostatin (Yamaguchi et al, 1999;
Rehn et al, 2001; Wickstrom et al, 2001; Dixelius et al, 2002;
Furumatsu et al, 2002; Hanai et al, 2002; Sasaki et al, 2002).
However, it is unclear whether and to what extent these activities
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Figure 3 (A) Intravital microscopy images recorded 15min after
injection of fluorescent tumour cells into the spleen of a control liver and
a liver after 2h rh-E pretreatment. (B) Number of fluorescent tumour cells
that are present in the liver per hpf as measured by intravital microscopy
15min and 1h after intrasplenic injection. Recombinant human endostatin
reduced the number of arrested tumour cells in the liver by 56%
(Po0.001). No differences were observed within either treatment group
between the two time points (controls 15min vs 1hP¼0.93; endostatin
15min vs 1hP¼0.39).
Endostatin
Citrate
0
100
200
300
N
o
.
 
o
f
 
a
d
h
e
r
e
d
 
t
u
m
o
u
r
c
e
l
l
s
 
m
m
–
2
Citrate Endostatin AB
HUVEC c-26
Figure 4 Recombinant human endostatin reduces tumour cell adhesion under flow conditions. (A) C26 cells were allowed to adhere to a confluent layer
of TNF-a-stimulated HUVECs under flow conditions for 5min and this was recorded on a videotape. The number of adherent tumour cells per mm
2 was
determined by off-line analysis of the video images. Recombinant human endostatin reduced the number of adhered tumour cells to stimulated HUVECs
when compared to citrate buffer control by 41% (P¼0.04). (B) Immunofluorescence and multiphoton laser scanning microscopy visualised C26 tumour cell
adhesion to HUVECs. After perfusion with tumour cells in full blood, the coverslips were fixed and stained with Hoechst (blue) to stain nuclei, Phalloidin-
TRITC (red) to stain filamentous actin and anti-fibrinogen (green) to visualise the extracellular matrix. Platelets are indicated by arrows.
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scontribute to early antiangiogenic and antimetastatic effects.
Undisturbed early tumour cell metastasis is a multistep process
that requires intravascular arrest of tumour cells, as well as
their adhesion to endothelial cells, followed by transendothelial
migration. All of these aforementioned steps – in theory – can
be potential targets by which early metastasis formation is
inhibited.
In this study, we show that early treatment with endostatin
led to inhibition of the number of tumour cells arrested in
the liver within 15min after intrasplenic tumour cell injection,
which in turn resulted in enhanced antitumour efficacy. In vitro,
endostatin neither affected the migration nor caused cell death of
the tumour cells. There was, however, a strong inhibitory effect of
endostatin pretreatment on the adhesion of tumour cells to
endothelial cells under flow conditions. These data cannot be
explained by classical ‘antiangiogenesis’ activity. Therefore, our
studies provide evidence for a novel mechanism of endostatin
action, in addition to its direct effects on angiogenesis and
endothelial cells.
In vitro experiments mainly focused on endostatin and
endothelial cell–cell adhesion revealed an integrin-dependent
interaction (Rehn et al, 2001; Furumatsu et al, 2002). Possibly
our findings demonstrating that endostatin inhibits adhesion of
tumour cells to endothelial cells and diminishes intrahepatic
tumour cell arrest are integrin mediated. This explanation is
supported by the findings of Rehn et al, who demonstrated that
endostatin interacts with a5b1, avb3 and avb5 integrins on the
surface of HUVECs. Others found that endostatin activity is
mediated by an integrin-dependent inhibition of adhesion of
endothelial cells to collagen I (Furumatsu et al, 2002). Indeed, the
recent study on the effects of endostatin on experimental
melanoma cells showed that VCAM-1 plays an important role in
adhesion of these cells (Mendoza et al, 2004). Interestingly, in a
study on the mapping of endostatin binding sites in intact human
tissues, endostatin was predominantly found to bind to blood
vessels (Chang et al, 1999). Inhibitory effects of tumour cell
adhesion to HUVEC by endostatin are not likely to be explained by
a direct effect of endostatin on TNF-a upregulation, since this
pathway was observed not to be influenced by endostatin (Yin et al,
2002).
Furthermore, the ability of endostatin to bind to the proteogly-
can heparin (O’Reilly et al, 1997) points to a possible involvement
of heparin sulphate proteoglycans (HSPGs) in endostatin activity.
These are expressed on the cell surface or present in the
extracellular matrix (ECM) and mediate the adhesion of cells to
other cells or ECM (Ma and Geng, 2000; Engbring et al, 2002).
Indeed, heparin and heparan sulphate can inhibit experimental
tumour metastasis (reviewed in Engelberg, 1999).
On the other hand, one cannot rule out that alternative steps to
adhesion could be of importance in early metastasis. Intravascular
tumour cell arrest, through direct interactions of tumour cells with
components of the blood, can mediate dissemination. Tumour cell
arrest can be affected by fibrin deposition (Palumbo and Degen,
2001), as well as platelets–tumour cell interaction (Honn et al,
1992). We could speculate that the binding of platelets to the
tumour cells is inhibited, possibly mediated by integrins as well.
The relative contribution of fibrinogen-, platelet- and endothelial
cell-mediated interactions with tumour cells will have to be
elucidated in in vivo experiments using mice that lack components
of the fibrinolytic system.
As in a previous study, we found that endostatin is effective
against colorectal liver metastases (te Velde et al, 2002).
Solaun et al showed that the antiangiogenic mechanism (i.e.
endothelial cell apoptosis) was selective for sinusoidal-type
metastases, in which the neovasculature originating from sinusoi-
dal endothelium cells was targeted by endostatin. Differences in
the tumour’s microenvironment are known to determine anti-
tumour efficacy of the treatment (Fidler, 1978, 1999) The precursor
of endostatin, the long form of collagen XVIII, is almost
exclusively found in the liver (Saarela et al, 1998) and mainly
expressed by hepatocytes (Schuppan et al, 1998; Lietard et al,
2000). Continuous capillaries contain both XV and XVIII collagen,
but fenestrated capillaries (e.g. liver sinusoids, glomeruli, lung
alveoli and splenic sinusoids) express only type XVIII (Tomono
et al, 2002). In our hands, endostatin had no effect on
subcutaneous tumours, possibly because the outgrowth of these
tumours does not depend on cell seeding (data not shown; see also
Schmitz et al, 2004). We could speculate that endostatin action in
the liver is mediated by dominant-negative competition with its
precursor. Such insights into organ specificity might be useful in
the design of future clinical trials. Furthermore, since we found
optimal antitumour effects even as early as within 15min after
intrasplenic tumour cell injection, endostatin prophylaxis might
prove very promising to augment surgical treatment of colorectal
carcinoma and liver metastases. Even in no-touch surgery,
preventing metastatic seeding and combined with mesenterical
vessel ligation, 12.5% of patients have detectable tumour spill in
the circulation (Sales et al, 1999). Overall, as many as 75% of
colorectal cancer patients develop liver metastases (Pickren et al,
1982). In this respect, it is worth mentioning that clinical trials in
patients with established metastatic disease have shown that
endostatin, although well tolerated, generated marginal tumour
responses (Eder et al, 2002; Herbst et al, 2002; Thomas et al, 2003).
Others also found that the efficacy of endostatin improved when
administered before tumour cell injection, as measured by tumour
load 21 days following tumour cell injection (Solaun et al, 2002).
Bergers et al (1999) correspondingly showed that endostatin,
among others, was capable of treating early stages of cancer.
Finally, in vivo endostatin gene transfection with a cationic lipid
inhibited the outgrowth of fibrosarcoma cells as pulmonary
metastases and this was most effective when treatment was started
prior to tumour cell inoculation (Yano et al, 2004). Taken together,
it seems likely that endostatin efficacy will be optimal when
administered during the early stages of the disease. Therefore, the
antitumour activity of endostatin should be further tested in
patients with minimal or microscopic metastatic disease. In vitro
studies provide evidence to support an early effect of endostatin:
disassembly of focal adhesions and actin stress fibres in
endothelial cells in vitro was described to be already visible 1h
after endostatin administration (Wickstrom et al, 2001). In
addition, early-response genes responsible for cell–matrix inter-
actions were downregulated rapidly after endostatin treatment
(Shichiri and Hirata, 2001).
In conclusion, 2-h pretreatment in vivo with endostatin inhibits
intrahepatic tumour growth, mainly due to early (o15min)
inhibition of tumour cell seeding in the liver. It also induces a
two-fold decrease of tumour cell adhesion to endothelial cells
under flow conditions. This appears to be a novel, nonangiogen-
esis-related working mechanism of endostatin, possibly mediated
by integrin-dependent adhesion of tumour cells to endothelial
cells. These data can be helpful in the design of future clinical trials
to augment surgical treatment of colorectal carcinoma and liver
metastases.
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